Cortisol inhibits cholinergic vasodilatation in the human forearm

• Published in: American journal of hypertension 2000-11, Vol.13 (11), p.1155-1160
• Main Authors: Mangos, George J, Walker, Brian R, Kelly, John J, Lawson, Jane A, Webb, David J, Whitworth, Judith A
• Format: Article
• Language: English
• Subjects: acetylcholine; Arterial hypertension. Arterial hypotension; Biological and medical sciences; Blood and lymphatic vessels; Cardiology. Vascular system; Clinical manifestations. Epidemiology. Investigative techniques. Etiology; forearm blood flow; Glucocorticoid; hypertension; Medical sciences; nitric oxide
• ISSN: 0895-7061; 1879-1905; 1941-7225
• DOI: 10.1016/S0895-7061(00)01201-2

Exogenous cortisol raises blood pressure (BP) in humans and there is accumulating evidence of abnormalities of glucocorticoid activity in essential hypertension. In this study we tested the hypothesis that exogenous cortisol attenuates the cholinergic dilator response in the forearm circulation. Fourteen healthy normotensive men were studied. Using bilateral forearm venous plethysmography, we examined forearm blood flow responses to intra-arterial acetylcholine (ACh) and sodium nitroprusside (SNP) pre- and post- N G -monomethyl- l-arginine (LNMMA) after 2 or 5 days of oral cortisol or placebo in a randomized, double-blind crossover study. Exogenous cortisol increased supine systolic ( P < .05) and standing systolic ( P < .05) BP and produced expected metabolic changes and suppressed serum cortisol concentration ( P < .001). Baseline forearm blood flow did not differ between placebo and cortisol treatments at 2 or 5 days. Cholinergic vasodilatation was impaired after cortisol administration, reaching statistical significance at 5 days ( P < .05). Cortisol did not affect responses to SNP. N G -monomethyl- l-arginine inhibited cholinergic vasodilatation in placebo-treated groups but had no additional effect in the presence of cortisol. These results support our hypothesis and suggest that the mechanism of impaired cholinergic dilatation in glucocorticoid-treated subjects involves abnormalities of the endothelial nitric oxide system.